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We studied whether MF59-adjuvanted inﬂuenza vaccine improves immunity against drifted inﬂuenza strains in institutionalised
elderly with underling chronic health conditions. Sera from a randomized study, comparing MF59-adjuvanted (Sub/MF59,
n = 72), virosomal (SVV, n = 39), and split (n = 88) vaccines, were retested using a hemagglutination inhibition (HI) assay
against homologous (Northern Hemisphere [NH] 1998/99) and drifted (NH 2006/07) strains. Corrected postvaccination HI
antibody titres were signiﬁcantly higher with Sub/MF59 than SVV for all strains; GMTs against homologous A/H3N2 and B
and both drifted A strains were signiﬁcantly higher for Sub/MF59 than split. Seroprotection rates and mean-fold titer increases
were generally higher with Sub/MF59 for all A inﬂuenza strains. MF59-adjuvanted inﬂuenza vaccine induced greater and broader
immuneresponsesinelderlypeoplewithchronicconditions,thanconventionalvirosomalandsplitvaccines,particularlyforA/H1
and A/H3 strains, potentially giving clinical beneﬁt in seasons where antigenic mismatch occurs.
1.Introduction
The frequency and severity of infectious diseases, including
inﬂuenza, increase with old age. The elderly are particularly
vulnerable to inﬂuenza and this highly contagious infectious
disease causes a high frequency of morbidity and mortality
in older individuals [1–4]. The mortality rate in the elderly
is particularly high compared with the general population,
with 95% of all inﬂuenza-related deaths occurring in the
elderly, primarily in those with underlying chronic health
conditions [5].
Groupsathigh-riskofcomplicationsofinﬂuenzainclude
patients with cardiovascular or pulmonary conditions,
metabolic diseases, and the institutionalized [6]. In fact,
inﬂuenza can exacerbate underlying diseases in the elderly
population, being the likely primary cause of the winter-
season increase in mortality in patients with ischemic
heart disease, cerebrovascular disease and diabetes mellitus
[7, 8].
Annual vaccination is the recommended method to
prevent inﬂuenza; the WHO has suggested that vaccina-
tion can reduce inﬂuenza-related morbidity by 60% and2 Clinical and Developmental Immunology
inﬂuenza-related mortality by 70–80% [9]. However, cur-
rentlyavailableinﬂuenzavaccineshavedemonstratedlimited
eﬃcacy in the elderly, mainly because of the waning immune
response typical with advancing age [10–12]. Indeed, lower
IgA and IgG antibody responses, delayed peak antibody
titers, and a faster decline in titers following vaccination are
observed, especially in very old and frail persons [13].
The continual evolution of the inﬂuenza virus also
impacts on the eﬀectiveness of inﬂuenza vaccines. Antigenic
drift frequently occurs in inﬂuenza A and B subtypes and
the impact of this drift on vaccine eﬀectiveness in the elderly
is considered very high [14–16]. It has been suggested that
antigenic drift is associated with a more severe and early
onset of inﬂuenza epidemic, since the level of preexisting
immunity to the drifted strain is reduced [17]. In elderly
subjects seroprotection rates can be as low as 20% against
drifted strains, dropping from ≥70% in years where a good
antigenic match is observed [18–21].
Meeting the challenge presented by waning immunity in
the elderly requires vaccines that oﬀer enhanced immuno-
genicity andincreasedclinical protection, suchasadjuvanted
inﬂuenza vaccines. Formulation of a subunit inﬂuenza
vaccine with the MF59 adjuvant has been shown to enhance
immunogenicity and oﬀer broader serological protection in
theelderlycomparedwithconventionalnon-adjuvantedvac-
cines, especially versus the most epidemiologically prevalent
A/H3N2 inﬂuenza viruses [6, 20, 22].
This study was performed to assess the immunogenicity
of three inactivated inﬂuenza vaccines, a MF59-adjuvanted
subunit vaccine (Sub/MF59; FLUAD, Novartis Vaccines),
a virosomal vaccine (SVV; InﬂexalV,S w i s sS e r u ma n d
VaccineInstitute),andasplitvaccine(Split;Mutagrip,P as-
teur Merieux MSD), against homologous and heterologous
strains, by retesting sera of elderly nursing home residents
with chronic underlying conditions, who participated in a
previous randomized, controlled trial [6].
2.MaterialsandMethods
Sera from a subset of 199 elderly nursing home residents
(≥65 years of age) previously enrolled in a randomized, con-
trolled trial performed during the winter season of 1998/99
[6], were reanalyzed to test the immunogenicity conferred by
MF59-adjuvanted inﬂuenza vaccine (Sub/MF59; n = 72), by
a virosomal (SVV, n = 39) and a split (Split; n = 88) vaccines
against homologous and heterologous inﬂuenza strains.
During the clinical study, after obtaining informed
consent, blood samples (approximately 10mL) were drawn
prior to and 4 weeks after vaccination. Sera were stored at
−20
◦C until laboratory determination of HI antibody titres,
as described elsewhere [23].
All subjects received a single 0.5mL intramuscular (IM)
dose of Sub/MF59, virosomal or split vaccine in the deltoid
region of the non-dominant arm. Each vaccine dose con-
tained 15μg of hemagglutinin of each of the inﬂuenza strains
recommended by the WHO for the 1998/99 Northern Hemi-
sphere (NH) inﬂuenza season: A/Sydney/5/97(A/H3N2)-like
virus, A/Beijing/262/95(A/H1N1)-like virus and B/Beijing/
184/93-like virus.
A/H1N1
A/Beijing/262/1995
A/New Caledonia/20/1999
A/Bayern/7/1995
A/H3N2
A/Sydney/5/1997
A/Wuhan/359/95
A/Moscow/10/1999
A/Panama/2007/1999
A/Fujian/411/2002
A/Wyoming/03/2003
A/California/7/2004
A/Wisconsin/67/2005
B
B/Sichuan/379/99
B/Yamanashi/166/98
B/Beijing/184/93
B/Jiangsu/10/03
B/Malaysia/2506/2004
B/Hong Kong/330/2001
0.005
The strains tested are reported in bold, with the heterologous strains
in Italics.
Figure 1: Hemagglutinin phylogenetic trees of the strains recom-
mended for NH vaccine formulation from 1997/1998 to 2006/2007
inﬂuenza seasons.
The study was conducted in compliance with the Italian
Law Decree on the protection of personal data.
2.1. Assessment of Vaccine Immunogenicity. The current
analysistestedtheimmunogenicityusingtheHIassayagainst
the homologous 1998/99 strains and the heterologous viral
strains recommended for the 2006/07 NH inﬂuenza season
[A/Wisconsin/67/2005 (A/H3N2)-like virus; A/New Caledo-
nia/20/99 (A/H1N1)-like virus and B/Malaysia/2506/2004-
like virus]. The heterologous B strain selected for immuno-
genicity analyses belongs to the B/Victoria/2/87 lineage,
whereas the B strain included in the vaccine formulation
(B/Beijing) was from the alternative phylogenetic line of
B/Yamagata/16/88, with a previously reported lack of cross-
reactivitybetweenantibodiesforthesetwodivergentlineages
[24].
Phylogenetic trees of the inﬂuenza strains analyzed in
the study (both homologous and heterologous), including
the vaccine strains recommended for NH formulation from
1997/98to2006/07inﬂuenzaseasons,wasbasedonsequence
analysis of the region codifying for the hemagglutinin
(Figure 1). Data on inﬂuenza strains was obtained from the
website of the National Institute of Allergy and Infectious
Diseases-funded Inﬂuenza Research Database (NIAID IRD;
http://www.ﬂudb.org), and phylogenetic analyses were con-
ducted using the software Molecular Evolutionary Genetics
Analysis (MEGA), version 4.0 [25].Clinical and Developmental Immunology 3
The study parameters considered as expression of hu-
moral immune response were: the Geometric Mean Titers
(GMTs)ofHIantibodieswith95%conﬁdenceintervals(CI);
post-vaccination mean-fold increase (MFI) in HI antibodies
(ratio of post- to pre-vaccination titres); the number of
subjects with protective HI antibody level (titre ≥ 40 was
considered protective); and the number of subjects with at
least a 4-fold increase in post-vaccination titres.
2.2. Statistical Analysis. Data were analyzed using the Sta-
tistical Package for the Social Sciences (SPSS, Chicago, IL,
USA). The chi-square test was performed to analyze diﬀer-
encesbetweenproportionsofsubjects.Statisticalsigniﬁcance
between pre- and postvaccination titres was calculated using
the paired Student’s t-test. Comparison of diﬀerent vaccine
groups was determined by Student’s t-test for unpaired data.
A multivariate logistic regression analysis was carried
out for each virus strain to determine variables that are
independently associated with the likelihood of a person
achieving at least a 4-fold increase in HI titres. A P-value of
<.05 was considered to indicate statistical signiﬁcance, with
an odds ratio (OR) of <1 signifying that a person was less
likely to achieve a 4-fold increase.
Correction of the GMTs for pre-vaccination status
was performed: absolute titres were divided by 5 (i.e.,
undetectable titre <10) and then transformed to binary
logarithms. On this scale, an undetectable (seronegative)
titre represents “0”, a titre of 10 represents “1”, a titre of 20
represents “2”, and so forth, HI titres were transformed into
binarylogarithmsandcorrectedforpre-vaccinationstatusas
described by Beyer et al. [26].
3. Results
Sera were available from 199 elderly who took part into the
original study, and were retested for these new immuno-
genicity analyses for the Sub/MF59 (n = 72), SVV (n = 39)
and Split (n = 88) groups. According to the original baseline
characteristics more healthy subjects populated the split
group, compared with Sub/MF59 and SVV. The majority of
subjects in these last two groups (87.5% and 79.5%, resp.)
had at least one underlying chronic condition, including
cardiac and pulmonary conditions, or diabetes mellitus.
More than 80% of subjects in each group were >75 years
of age. The demographic characteristics of the subjects,
recorded at time of the original study, are summarized in
Table 1.
No statistically signiﬁcant diﬀerences were found in
terms of baseline GMTs between vaccine groups versus
homologous or heterologous strains.
The antibody responses are shown in Table 2 and
Figure 2, according to viral strain and vaccine group. Vac-
cination elicited higher GMTs against all strains, in all three
vaccination groups (Figure 2).
3.1. Immunogenicity against Homologous Strains. Very high
seroprotection rates (SP) were achieved by all three vaccines
(Table 2), but vaccination with Sub/MF59 resulted in slightly
but consistently higher postvaccination GMTs than the other
Table 1: Baseline characteristics of the study groups.
Subgroup
Sub/MF59
(n = 72) Split (n = 88) SVV (n = 39)
n (%) n (%) n (%)
Age group, years
≤85 31 (43.1) 42 (47.7) 11 (28.2)
>85 41 (56.9) 46 (52.3) 28 (71.8)
Gender
Males 5 (6.9) 24 (27.3) 0 (0.0)
Females 67 (93.1) 64 (72.7) 39 (100)
Previously vaccinated
No 12 (16.7) 16 (18.2) 2 (5.1)
Yes 60 (83.3) 76 (81.8) 37 (94.9)
Underlying disease
No 9 (12.5) 35 (39.8) 8 (20.5)
Yes∗ 63 (87.5) 53 (60.2) 31 (79.5)
Heart condition 51 (70.8) 49 (55.7) 24 (61.5)
Lung condition 42 (58.3) 11 (12.5) 17 (43.6)
Diabetes mellitus 12 (16.7) 8 (9.1) 3 (7.7)
Other 14 (19.4) 2 (2.3) 9 (23.1)
∗More than one risk status was possible for each subject.
two vaccination groups (Figure 2). In particular, Sub/MF59
induced statistically signiﬁcantly higher HI antibody titers
for all three strains, than those of the SVV vaccine group.
T h eG M T sw e r es u b s t a n t i a l l yc o n ﬁ r m e da f t e rc o r r e c t i o nf o r
baseline titers (Figure 3), and Sub/MF59 vaccine showed
the ability to induce statistically signiﬁcant (P < .01) higher
GMTs against A/H3 and B homologous strains, compared to
the split vaccine.
Postvaccination mean-fold increases in HI antibodies
were greater with Sub/MF59 compared with both virosomal
and split vaccines (Table 2).
Signiﬁcantly more subjects achieved at least a 4-fold
increase in HI titres against the homologous B strain
following Sub/MF59 vaccination, than the virosomal vaccine
(66.7% versus 46.2%, resp., P = .03) (Table 2).
3.2. Immunogenicity against Heterologous Strains. Consis-
tently higher GMTs were reported in the Sub/MF59 group,
and these values were statistically signiﬁcant for the A/H3N2
and A/H1N1 strains (Figure 2), compared with both non-
adjuvanted vaccines. After Beyer’s correction, the HI anti-
body titers against B strains were signiﬁcantly higher in the
Sub/MF59 than in the virosomal group.
Post-vaccination mean-fold increases in HI antibodies
were greater with Sub/MF59 compared with the other two
vaccine groups against all the three inﬂuenza virus variants
(Table 2).
Seroprotection rates induced by Sub/MF59 group were
higher than those after the SVV injection for both A strains
(P < .01 versus H1N1, P < .05 versus A/H3N2). Similar SP
rates against the B drifted strain were found in the three
vaccine groups.4 Clinical and Developmental Immunology
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Figure 2: GMTs against homologous and heterologous inﬂuenza strains, according to vaccine group.
Signiﬁcantly more subjects achieved at least a 4-fold
increase in titres following Sub/MF59 vaccination against all
three heterologous strains compared with SVV, and against
both A drifted strains when compared with split group
(Table 2) .T h er a t eo f4 - f o l di n c r e a s ei nH It i t e r sv e r s u sB
heterologousstrainwassigniﬁcantlyhigherinthesplitgroup
compared with SVV, and similar to the Sub/MF59 group.
AsshowninTable 3,themultivariateanalysisofvariables
associated with 4-fold increase in HI antibody titers revealed
that the presence of previous vaccination, only for the B
strain, and the type of vaccine used, for all strain, were
strong predictors of immune response against heterologous
inﬂuenza strains.
4. Discussion
Vaccination is of crucial importance in preventing infection
and protecting the vulnerable elderly population from
disease but, over the past decade, a large number of studies
have shown that antibody responses after vaccination are
lower in elderly persons than in young adults, and that
a variety of vaccines are less eﬃcient in elderly persons
[27].
Althoughtherelationshipbetweenspeciﬁcanti-inﬂuenza
virus antibody levels and clinical protection is intrinsically
variable [28], with other factors contributing to protection,
such as antibodies to neuraminidase [29]a n dc e l l u l a r
immunity [30], antibody titers against hemaglutinin and
derived surrogate end-points are currently considered the
basis for licensure of inﬂuenza vaccines in the diﬀerent age
groups.
The use of an adjuvant to enhance the antibody response
has been considered for a long time to be a valid option to
increasetheeﬃcacyofinﬂuenzavaccines[31,32].Preclinical
studies have shown that the adjuvant MF59 is internalized
by dendritic cells at the site of injection and facilitates
internalization of the antigen to enhance the immune
response and produce more antibodies.
This study was performed to evaluate the immuno-
genicity, using a validated HI assay, of three diﬀerent
inactivated inﬂuenza vaccines against both homologous and
heterologous inﬂuenza strains in all evaluable sera from
an original trial in nursing elderly residents with chronic
underlying diseases. The original study population mainly
comprisedveryelderlyindividuals,mostofthemwithatleast
one underlying medical condition.
Although the sera were retested approximately 10 years
after the original study, the data clearly conﬁrmed the
previous published evaluations vs. homologous antigens,
showing higher immunogenicity in the adjuvanted vaccine
group and the lower immune responses in the virosomal
group [6]. After correction according to pre-vaccination
status, a statistically signiﬁcant diﬀerence in HI titers was
evidentinfavorofMF59-adjuvantedvaccineagainstallthree
vaccine strains, when compared with the split vaccine, and
against A/H3N2 and B antigens when compared with the
split vaccine. Although all three inactivated vaccines induced
very high seroprotection rates, 4-fold increase in titers
was consistently higher in the MF59-adjuvanted vaccine
group.
In addition, the MF59-adjuvanted inﬂuenza vaccine
induced a higher level of immunogenicity against strainsClinical and Developmental Immunology 5
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Figure 3: Corrected GMTs against homologous and heterologous inﬂuenza strains, according to vaccine group.
that bear no close antigenic similarity to those included in
the vaccine formulation. For both heterologous A inﬂuenza
strains,Sub/MF59inducedsigniﬁcantlyhigherHIantibodies
and 4-fold increases in titers than the two non-adjuvanted
comparators. For the B drifted strain, signiﬁcantly higher HI
titers were induced by MF59 adjuvanted vaccine, compared
with SVV, and both adjuvanted and conventional split
vaccineshowedthehighestincreasesintiters,comparedwith
the virosomal vaccine.
Multivariate analysis also revealed that the presence of
previous vaccination and the type of vaccine used were
strong predictors of immune response against heterologous
inﬂuenza strains (Table 3).
All vaccines fulﬁlled all three CHMP criteria for elderly
against homologous strains. Against A heterologous anti-
gens, only Sub/MF59 fulﬁlled all CHMP criteria versus
A/H3N2 and A/H1N1 strains, SVV met all criteria against
A/H1N1 and none of them for A/H3N2, Split vaccine6 Clinical and Developmental Immunology
Table 2: Mean Fold Increase in titres (MFI), Seroprotection (≥40), and 4-fold increase rates according to viral strain and vaccine group.
Viral strain Vaccine MFI After vaccination (%)
Titre ≥ 40 4-fold
A/H1N1-like virus
A/Beijing/262/95
(Homologous) Sub/MF59 8.7 100 94.4
SVV 6.3 100 84.6
Split 7.7 98.9 85.2
A/New Caledonia/20/99
(Heterologous) Sub/MF59 6.1 87.5
∗
68.1 ∗∗
∗ SVV 2.9 82.1 43.6
Split 2.4 68.2 31.8
A/H3N2-like virus
A/Sydney/5/97
(Homologous) Sub/MF59 5.5 77.8 76.4
SVV 4.2 74.4 61.5
Split 4.2 79.5 62.5
A/Wisconsin/67/2005
(Heterologous) Sub/MF59 3.1 79.2 ∗∗
∗∗
41.7 ∗∗
∗∗ SVV 2.0 56.4 22.9
Split 2.0 78.4 27.3
B-like virus
B/Beijing/184/93
(Homologous) Sub/MF59 3.8 100 66.7
∗∗
SVV 2.9 97.4 46.2
Split 3.3 97.7 54.5
B/Malaysia/2506/2004
(Heterologous) Sub/MF59 2.0 69.4 25.0 ∗∗
∗∗ SVV 1.5 71.8 7.7
Split 1.9 73.9 26.1
∗P < .01; ∗∗P < .05.
Table 3: Multivariate analysis of variables associated with 4-fold HI-antibody titer increases according to heterologous virus strains.
Variables A/H1N1/NewCaledonia/20/99 A/H3N2/Wisconsin/67/2005 B/Malaysia/2506/2004
OR 95% CI OR 95% CI OR 95% CI
Age (<85) 0.784 (0.421–1.458) 1.515 (0.829–2.768) 0.681 (0.344–1.347)
Gender (males) 0.465 (0.177–1.219) 1.280 (0.507–3.234) 1.239 (0.463–3.317)
Underlying diseases 1.431 (0.783–2.615) 0.897 (0.490–1.644) 1.598 (0.811–3.149)
Previous vaccinations 1.447 (0.738–2.835) 0.806 (0.417–1.559) 0.307 (0.151–0.626)
Prevaccination titre (≥1:40) 1.803 (0.976–3.333) 0.676 (0.355–1.286) 0.891 (0.447–1.776)
Split versus Sub/MF59 0.287 (0.150–0.547) 0.436 (0.226–0.842) 0.795 (0.404–1.564)
SVV versus Sub/MF59 0.400 (0.180–0.893) 0.402 (0.167–0.965) 0.215 (0.060–0.774)
fulﬁlled only one criterion against both antigens. Against
B drifted strain only one criterion was met (seroprotection
rate) by all vaccines tested.
In conclusion, data from these immunogenicity analyses
conﬁrmed that MF59-adjuvanted inﬂuenza vaccine can oﬀer
greater and broader immunogenicity against inﬂuenza in
elderly and very elderly individuals who are at high risk of
inﬂuenza-related complications.
Studies to further evaluate the relationship between
vaccines-induced immunogenicity against homologous and
heterologous strains and clinical protection are clearly war-
ranted.Clinical and Developmental Immunology 7
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